These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 20813820)

  • 1. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort.
    Green J; Czanner G; Reeves G; Watson J; Wise L; Beral V
    BMJ; 2010 Sep; 341():c4444. PubMed ID: 20813820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposure to bisphosphonates and risk of gastrointestinal cancers: series of nested case-control studies with QResearch and CPRD data.
    Vinogradova Y; Coupland C; Hippisley-Cox J
    BMJ; 2013 Jan; 346():f114. PubMed ID: 23325866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates and risk of upper gastrointestinal cancer--a case control study using the General Practice Research Database (GPRD).
    Wright E; Schofield PT; Seed P; Molokhia M
    PLoS One; 2012; 7(10):e47616. PubMed ID: 23112825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Bisphosphonates and Upper Gastrointestinal Cancer Risks in Asians with Osteoporosis: A Nested Case-Control Study Using National Retrospective Cohort Sample Data from Korea.
    Jung SY; Sohn HS; Park EJ; Suh HS; Park JW; Kwon JW
    PLoS One; 2016; 11(3):e0150531. PubMed ID: 26937968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exposure to oral bisphosphonates and risk of esophageal cancer.
    Cardwell CR; Abnet CC; Cantwell MM; Murray LJ
    JAMA; 2010 Aug; 304(6):657-63. PubMed ID: 20699457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonate use and gastrointestinal tract cancer risk: meta-analysis of observational studies.
    Oh YH; Yoon C; Park SM
    World J Gastroenterol; 2012 Oct; 18(40):5779-88. PubMed ID: 23155320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of medications which cause inflammation of the gastro-oesophageal tract on cancer risk: a nested case-control study of routine Scottish data.
    Busby J; Murchie P; Murray L; Iversen L; Lee AJ; Spence A; Watson MC; Cardwell CR
    Int J Cancer; 2017 Apr; 140(8):1828-1835. PubMed ID: 28120338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral bisphosphonates and upper gastrointestinal toxicity: a study of cancer and early signals of esophageal injury.
    Morden NE; Munson JC; Smith J; Mackenzie TA; Liu SK; Tosteson AN
    Osteoporos Int; 2015 Feb; 26(2):663-72. PubMed ID: 25349053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure to oral bisphosphonates and risk of gastrointestinal cancer.
    Choi D; Choi S; Chang J; Park SM
    Osteoporos Int; 2020 Apr; 31(4):775-782. PubMed ID: 32034451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study.
    Coloma PM; de Ridder M; Bezemer I; Herings RM; Gini R; Pecchioli S; Scotti L; Rijnbeek P; Mosseveld M; van der Lei J; Trifirò G; Sturkenboom M;
    Osteoporos Int; 2016 May; 27(5):1857-67. PubMed ID: 26694594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral bisphosphonates and oesophageal cancer.
    Wysowski DK
    BMJ; 2010 Sep; 341():c4506. PubMed ID: 20813821
    [No Abstract]   [Full Text] [Related]  

  • 12. Incident acute pseudogout and prior bisphosphonate use: Matched case-control study in the UK-Clinical Practice Research Datalink.
    Roddy E; Muller S; Paskins Z; Hider SL; Blagojevic-Bucknall M; Mallen CD
    Medicine (Baltimore); 2017 Mar; 96(12):e6177. PubMed ID: 28328803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonate therapy start may transiently increase the risk of tendon rupture in patients with glucocorticoid co-medication: a population-based observational study.
    Spoendlin J; Meier C; Jick SS; Meier CR
    Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1116-1123. PubMed ID: 27297005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis: oral bisphosphonates and the risk of oesophageal cancer.
    Andrici J; Tio M; Eslick GD
    Aliment Pharmacol Ther; 2012 Oct; 36(8):708-16. PubMed ID: 22966908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral Bisphosphonate Exposure and the Risk of Upper Gastrointestinal Cancers.
    Vogtmann E; Corley DA; Almers LM; Cardwell CR; Murray LJ; Abnet CC
    PLoS One; 2015; 10(10):e0140180. PubMed ID: 26445463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of oral bisphosphonates and risk of venous thromboembolism: a population-based case-control study.
    Lamberg AL; Horvath-Puho E; Christensen S; Sørensen HT
    Osteoporos Int; 2010 Nov; 21(11):1911-7. PubMed ID: 19997902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study.
    Sørensen HT; Christensen S; Mehnert F; Pedersen L; Chapurlat RD; Cummings SR; Baron JA
    BMJ; 2008 Apr; 336(7648):813-6. PubMed ID: 18334527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exposure to oral bisphosphonates and risk of cancer.
    Cardwell CR; Abnet CC; Veal P; Hughes CM; Cantwell MM; Murray LJ
    Int J Cancer; 2012 Sep; 131(5):E717-25. PubMed ID: 22161552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occurrence of gastrointestinal cancer in users of bisphosphonates and other antiresorptive drugs against osteoporosis.
    Vestergaard P
    Calcif Tissue Int; 2011 Dec; 89(6):434-41. PubMed ID: 22002678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.